SynthesisInternational urology and nephrology2026
Androgen deprivation therapy with apalutamide in the treatment of metastatic castration-sensitive prostate cancer: the systematic review of its effectiveness and applicability for Asian men in the targeted investigational treatment analysis of novel anti-androgen (TITAN) trial.
Synthesis in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe TITAN trial established survival benefits of adding apalutamide to androgen deprivation therapy (ADT) in metastatic castration‑sensitive prostate cancer (mCSPC). Whether efficacy and safety are comparable in Asian men remains insufficiently characterized.
methodsWe conducted a PRISMA-guided review (PROSPERO CRD420251054772) and adhered to the SWiM framework for narrative synthesis. Databases searched in MEDLINE, Embase, Cochrane Library, and CINAHL from inception to 15 December 2024. Eligible studies presented Asian subpopulation outcomes for apalutamide + ADT in mCSPC from TITAN (final post hoc/data‑cut updates) and any independent Asian datasets. CASP critical appraisal was applied to selected studies; subgroup analysis was appraised for pre-specification, multiplicity, and reporting completeness. Overlapping publications were consolidated into the most mature dataset per endpoint.
resultsFour TITAN‑derived analysis met the inclusion criteria. In Asian patients (N = 221), apalutamide + ADT showed benefits directionally consistent with the overall population for overall survival (OS, HR 0.68, 95% CI 0.42-1.13, P = 0.1335) and radiographic progression‑free survival (rPFS, HR 0.506, 95% CI 0.302-0.849, P = 0.009). Prostate-specific antigen (PSA) responses (PSA ≤ 0.2 ng/mL, PSA 50/90 decline: 73.9%, 90.1%, 74.8% and early deep declines) favored apalutamide. Time to PSA progression (TTPP, HR: 0.21, 95% CI 0.13-0.35, P < 0.0001), time to castration resistance (TTCR, HR 0.3, 95% CI 0.21-0.46, P < 0.0001), and second progression-free survival (PFS2, HR 0.76, 95% CI 0.44-1.29, P = 0.3022) were significantly improved. Skin rash appeared higher in Asian patients (30.9% any grade; 5.5% grade ≥ 3), typically manageable with standard measures, with no new safety signals emerging.
conclusionAsian subpopulation efficacy with apalutamide + ADT is directionally consistent with TITAN overall, with higher rash frequency that is generally manageable. Small subpopulation size and overlapping publications limit precision; regionally representative real‑world studies are needed.
trial registrationPROSPERO number CRD420251054772.
Indexed as
Identifiers
41353294What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.